IU Indy Center Develops First Drug Therapy for Hydrocephalus
The Hydrocephalus Research Center at Indiana University Indianapolis is developing the first drug therapy for hydrocephalus, focusing on TRPV4 antagonists. This initiative, supported by $11.7 million from the U.S. Department of Defense, aims to reduce cerebrospinal fluid production and potentially mitigate neuroinflammation.
The center, which has grown to over 30 staff and students, has demonstrated the efficacy of TRPV4 antagonists in small-scale animal models. These compounds have shown promise in reducing cerebrospinal fluid production, a critical factor in managing hydrocephalus.
Current treatment for hydrocephalus primarily involves shunts, which fail in approximately 50% of pediatric cases within two years. The development of a drug therapy could address this significant limitation.
The research team plans to present their findings at the Hydrocephalus Association’s HA Connect conference in Indianapolis from July 23 to 25, 2026.